Cargando…

What, When and How to Measure—Peripheral Biomarkers in Therapy of Huntington’s Disease

Among the main challenges in further advancing therapeutic strategies for Huntington’s disease (HD) is the development of biomarkers which must be applied to assess the efficiency of the treatment. HD is a dreadful neurodegenerative disorder which has its source of pathogenesis in the central nervou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Przybyl, Lukasz, Wozna-Wysocka, Magdalena, Kozlowska, Emilia, Fiszer, Agnieszka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913877/ https://www.ncbi.nlm.nih.gov/pubmed/33557131 http://dx.doi.org/10.3390/ijms22041561

Ejemplares similares

Generation of New Isogenic Models of Huntington’s Disease Using CRISPR-Cas9 Technology
por: Dabrowska, Magdalena, et al.
Publicado: (2020)

Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts
por: Ciesiolka, Adam, et al.
Publicado: (2020)

What the Gut Tells the Brain—Is There a Link between Microbiota and Huntington’s Disease?
por: Wronka, Dorota, et al.
Publicado: (2023)

Regulatory Potential of Competing Endogenous RNAs in Myotonic Dystrophies
por: Koscianska, Edyta, et al.
Publicado: (2021)

Reduction of Huntington’s Disease RNA Foci by CAG Repeat-Targeting Reagents
por: Urbanek, Martyna O., et al.
Publicado: (2017)

Peripheral Biomarkers in Manifest and Premanifest Huntington’s Disease
por: Morena, Emanuele, et al.
Publicado: (2023)

Disease Onset in Huntington's Disease: When Is the Conversion?
por: Oosterloo, Mayke, et al.
Publicado: (2021)

What? When? And How?
por: Hutchinson, Jonathan
Publicado: (1890)

Morphological changes in bitches endometrium affected by cystic endometrial hyperplasia - pyometra complex – the value of histopathological examination
por: Woźna-Wysocka, Magdalena, et al.
Publicado: (2021)

Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood
por: Mastrokolias, Anastasios, et al.
Publicado: (2015)

Uric Acid as a Potential Peripheral Biomarker for Disease Features in Huntington’s Patients
por: Corey-Bloom, Jody, et al.
Publicado: (2020)

Why, what, who, when and how? Hand hygiene measured in India?
por: Hemalatha, J, et al.
Publicado: (2015)

The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine
por: Dirks, Niek F., et al.
Publicado: (2018)

All roads lead to cure: Diversity of oligonucleotides in DM1 therapy
por: Fiszer, Agnieszka
Publicado: (2023)

A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease
por: Kotowska-Zimmer, Anna, et al.
Publicado: (2022)

Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington’s Disease Patients
por: Gutierrez, Ashley, et al.
Publicado: (2020)

What to Eat, and What to Drink, and How, and When, and Where to Do It
por: Pratt, B. H.
Publicado: (1869)

A New Perspective on Huntington’s Disease: How a Neurological Disorder Influences the Peripheral Tissues
por: Gómez-Jaramillo, Laura, et al.
Publicado: (2022)

Citrate: How to Get Started and What, When, and How to Monitor?
por: Honore, Patrick M., et al.
Publicado: (2018)

Abnormal peripheral chemokine profile in Huntington’s disease
por: Wild, Edward, et al.
Publicado: (2011)

Advancing Teams Research: What, When, and How to Measure Team Dynamics Over Time
por: Delice, Fabrice, et al.
Publicado: (2019)

Expression of Transforming Growth Factor Beta Isoforms in Canine Endometrium with Cystic Endometrial Hyperplasia–Pyometra Complex
por: Rybska, Marta, et al.
Publicado: (2021)

Is TGF-β1 a Biomarker of Huntington’s Disease Progression?
por: Plinta, Klaudia, et al.
Publicado: (2021)

Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?
por: Kumarasamy, N., et al.
Publicado: (2011)

Surveillance in testicular cancer: who, when, what and how?
por: Sohaib, S.A., et al.
Publicado: (2007)

The Role of Words in Cognitive Tasks: What, When, and How?
por: Robinson, Christopher W., et al.
Publicado: (2012)

Treatment in advanced colorectal cancer: what, when and how?
por: Chau, I, et al.
Publicado: (2009)

Treatment strategies in axial spondyloarthritis: what, when and how?
por: Fragoulis, George E, et al.
Publicado: (2020)

Fungal Genomics in Respiratory Medicine: What, How and When?
por: Brackin, Amelie P., et al.
Publicado: (2021)

Immunotherapy in Breast Cancer: When, How, and What Challenges?
por: Henriques, Beatriz, et al.
Publicado: (2021)

Imaging for Plasma Cell Dyscrasias: What, When, and How?
por: Guha, Amrita, et al.
Publicado: (2022)

The sleep and circadian problems of Huntington’s disease: when, why and their importance
por: Voysey, Z., et al.
Publicado: (2020)

How to decide: what to do when you don't know what to do
por: Herring, Jonathan
Publicado: (2012)

Lp(a): When and how to measure it
por: Cegla, Jaimini, et al.
Publicado: (2020)

Sarcopenia: how to measure, when and why
por: Tagliafico, Alberto Stefano, et al.
Publicado: (2022)

Neural Image Analysis and Electron Microscopy to Detect and Describe Selected Quality Factors of Fruit and Vegetable Spray-Dried Powders—Case Study: Chokeberry Powder
por: Przybył, Krzysztof, et al.
Publicado: (2019)

What is the Pathogenic CAG Expansion Length in Huntington’s Disease?
por: Donaldson, Jasmine, et al.
Publicado: (2021)

Sleep Disorders in Huntington’s Disease
por: Herzog–Krzywoszanska, Radoslawa, et al.
Publicado: (2019)

A tutorial on methodological studies: the what, when, how and why
por: Mbuagbaw, Lawrence, et al.
Publicado: (2020)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o4mgsojuduap62v6dioajqfb60